{"analyses":[{"ciPctValue":"95","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0025","pValueComment":"The p value is two-sided from the log rank test stratified by the randomization stratification factors of IPSS classification and FAB classification.","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.53","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.87","estimateComment":"Cox proportional hazards model stratified on the randomization factors of FAB and IPSS with model term of treatment.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0027","paramType":"Hazard Ratio (HR)","paramValue":"0.68","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.9","upperLimit":"15.0","value":"13.02"},{"groupId":"OG001","lowerLimit":"5.4","upperLimit":"9.8","value":"7.61"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"179"}],"units":"Participants"}],"description":"The time to transformation to AML or death from any cause (whichever occurred first) was defined as the number of days from the date of randomization until the date of documented AML transformation or death from any cause. Patients who did not transform to AML or die were censored at the date of last follow-up.","dispersionType":"95% Confidence Interval","groups":[{"description":"Azacitidine, 75 mg/m\\^2/day given by subcutaneous injection for 7 days of every 28 day cycle, plus best supportive care.","id":"OG000","title":"Azacitidine"},{"description":"Physician choice of low dose cytarabine, standard chemotherapy, or best supportive care (consisting of blood products, growth factors, antibiotics)","id":"OG001","title":"Conventional Care"}],"paramType":"MEDIAN","populationDescription":"Intent to treat population. Participants who either transformed to AML or died are 120 for azacitidine and 132 for conventional care. Remaining participants were censored.","reportingStatus":"POSTED","timeFrame":"Day 1 (randomization) to 42 months","title":"Kaplan-Meier Estimate for Median Time to Transformation to Acute Myeloid Leukemia (AML) or Death From Any Cause, Whichever Occurred First","type":"SECONDARY","unitOfMeasure":"months"}